CA2655335C — Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
Assigned to Janssen Pharmaceutica NV · Expires 2016-09-06 · 10y expired
What this patent protects
The present invention provides a dosage form for administration to psychiatric patients in need of treatment with long acting injectable paliperidone palmitate formulations, as well as a paliperidone palmitate dosage delivery system for such formulations.
USPTO Abstract
The present invention provides a dosage form for administration to psychiatric patients in need of treatment with long acting injectable paliperidone palmitate formulations, as well as a paliperidone palmitate dosage delivery system for such formulations.
Drugs covered by this patent
- Invega Sustenna (PALIPERIDONE PALMITATE) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.